On this page
Canavan disease
This condition is a severe neurological disorder that typically appears in infancy, leading to developmental delays, intellectual disability, and other neurological problems. It is caused by genetic changes inherited in an autosomal recessive pattern.
Available at Jeen Health
Clinical tests that include this
Overview
Canavan disease is a rare, inherited condition that affects the brain, specifically the white matter, which is crucial for transmitting signals between nerve cells [PMID:31536340]. It is one of a group of disorders known as leukodystrophies, which are characterised by the destruction of myelin, the fatty protective sheath around nerve fibres. This damage to myelin disrupts the brain's ability to communicate effectively, leading to progressive neurological deterioration.
Most commonly, Canavan disease presents in infancy, with symptoms becoming apparent within the first few months of life. It can also, more rarely, manifest in a milder, juvenile or even adult form. The condition primarily affects individuals of Ashkenazi Jewish heritage, where a higher prevalence has been observed compared to the general population [PMID:20301387].
Symptoms & clinical features
The symptoms of Canavan disease often begin to show in early infancy, typically between 3 and 6 months of age. Infants may have a noticeable lack of head control and difficulty with motor skills such as rolling over or sitting up. A key feature is macrocephaly, meaning an unusually large head circumference, which can be an early indicator [PMID:31536340].
As the condition progresses, affected children often develop severe intellectual disability, an inability to communicate, and vision problems. Muscle tone can be affected, leading to floppiness (hypotonia) or stiffness (spasticity). Other common symptoms include feeding difficulties, seizures, and sleep disturbances. These symptoms tend to worsen over time due to the ongoing degeneration of the brain's white matter.
Video: Genetics 101
Affected organs
Canavan disease primarily affects the central nervous system, specifically the brain. The main impact is on the white matter of the brain, which is rich in myelin. Myelin acts as insulation for nerve fibres, allowing electrical impulses to travel quickly and efficiently. In Canavan disease, the myelin breaks down, impairing these vital neural connections.
This widespread demyelination affects various brain functions, leading to the diverse neurological symptoms observed. While other organs are not directly affected by the disease process, the neurological impact can indirectly affect functions like feeding and breathing, which are regulated by brain signals.
Risks & severity
Canavan disease is typically severe, with the infantile form being the most common and generally resulting in a short life expectancy, often into early childhood. While there are milder juvenile and adult forms, these are much rarer and show a slower progression of symptoms. The severity of the condition and the rate of progression can vary between individuals.
Prevalence figures suggest that Canavan disease is more common within populations of Ashkenazi Jewish descent, with an estimated prevalence of about 1 in 6,400 births in this group [PMID:20301387]. The exact prevalence in other populations is not well established but appears to be much lower. The age of onset usually falls within the first 3 to 6 months of life for the classic infantile form.
Genetic causes
Canavan disease is caused by pathogenic variants in the ASPA gene. This gene provides instructions for making an enzyme called aspartoacylase. This enzyme is primarily found in the brain and is crucial for breaking down a chemical called N-acetylaspartate (NAA) [PMID:31536340].
The aspartoacylase enzyme converts NAA into aspartate and acetate. Acetate is then used to produce fatty acids, which are essential components of myelin. When the ASPA gene has a pathogenic variant, the aspartoacylase enzyme either doesn't work correctly or isn't produced at all. This leads to a build-up of NAA in the brain, which is thought to be toxic to brain cells and interferes with myelin production and maintenance.
- ASPA aspartoacylase
Inheritance pattern
Canavan disease follows an autosomal recessive pattern of inheritance. This means that a person must inherit two copies of the altered ASPA gene - one from each parent - to develop the condition. Individuals who inherit only one copy of the altered gene are known as carriers. Carriers typically do not show any symptoms of Canavan disease because their one working copy of the gene produces enough of the aspartoacylase enzyme.
If both parents are carriers of a pathogenic variant in the ASPA gene, there is a 25% chance with each pregnancy that their child will inherit two altered copies and develop Canavan disease. There is a 50% chance the child will be a carrier, and a 25% chance the child will inherit two normal copies of the gene and not have the condition or be a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of Canavan disease often begins with a clinical suspicion based on the characteristic symptoms, such as developmental delay and macrocephaly, particularly in infancy. Magnetic Resonance Imaging (MRI) of the brain can reveal typical white matter abnormalities associated with the condition [PMID:20301387].
Confirmation of the diagnosis is typically achieved through genetic testing, which can identify pathogenic variants in the ASPA gene. Biochemical tests measuring elevated levels of N-acetylaspartate (NAA) in urine, blood, or cerebrospinal fluid can also support the diagnosis. In the UK, genetic testing for Canavan disease is available through the NHS Genomic Medicine Service, often initiated following referral by a paediatrician or neurologist to a clinical genetics service. This testing would generally fall under relevant R-codes for inherited white matter disorders.
Management & lifestyle
Currently, there is no cure for Canavan disease, and management focuses on providing supportive care to address symptoms and improve quality of life. This includes a multidisciplinary approach involving paediatricians, neurologists, physiotherapists, occupational therapists, and speech and language therapists. Treatment strategies focus on managing symptoms such as feeding difficulties, spasticity, and seizures.
Physiotherapy and occupational therapy can help maintain flexibility and manage muscle tone. Nutritional support, often through a gastrostomy tube if swallowing is difficult, is important to ensure adequate intake. Medication can be used to control seizures and manage muscle stiffness. Regular monitoring and care in line with NHS guidelines for rare neurological conditions are essential. Genetic counselling is also an important aspect of care, offering information and support to families.
UK care pathway
In the UK, individuals suspected of having Canavan disease would typically be referred by their GP or a specialist, such as a paediatrician or neurologist, to a clinical genetics service. This service can facilitate genetic testing through the NHS Genomic Medicine Service. The testing for Canavan disease would fall under specific R-codes associated with inherited metabolic disorders or leukodystrophies, as listed in the NHS National Genomic Test Directory (e.g., R323 'Early onset leukoencephalopathy').
Clinical geneticists and genetic counsellors play a vital role in coordinating diagnostic pathways, interpreting genetic test results, and providing information and support to families regarding inheritance patterns, risks for future pregnancies, and access to support networks. The NHS provides comprehensive care for individuals affected by rare conditions, often involving specialist centres.
Frequently asked questions
What is the typical life expectancy for someone with Canavan disease?
For the most common, severe infantile form of Canavan disease, life expectancy is often into early childhood, though some individuals may live longer with comprehensive supportive care. Milder forms are very rare and have a longer life expectancy.
Can Canavan disease be detected before birth?
Yes, if a family has a known history of Canavan disease and the specific genetic changes in the parents are identified, prenatal genetic testing can be performed during pregnancy. This usually involves chorionic villus sampling (CVS) or amniocentesis.
Are there any treatments for Canavan disease?
Currently, there is no cure for Canavan disease. Management focuses on supportive care to ease symptoms, such as physiotherapy, occupational therapy, and medications to manage seizures or muscle stiffness. Research into potential new treatments is ongoing.
How common is Canavan disease in the general population?
Canavan disease is rare in the general population. It is more prevalent within the Ashkenazi Jewish community, where approximately 1 in 6,400 individuals are affected, but its occurrence in other populations is much lower.
What does it mean to be a 'carrier' of Canavan disease?
Being a carrier means you carry one copy of the altered ASPA gene but do not show symptoms of the disease yourself. If both parents are carriers, they have a 25% chance with each pregnancy of having a child with Canavan disease.
References
- Thakkar RN, Patel D, Kioutchoukova IP. Leukodystrophy Imaging: Insights for Diagnostic Dilemmas. Medical sciences (Basel, Switzerland). 2024. PMID: 38390857
- Mendell JR, Al-Zaidy SA, Rodino-Klapac LR. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Molecular therapy : the journal of the American Society of Gene Therapy. 2021. PMID: 33309881
- Bokhari MR, Samanta D, Bokhari SRA. Canavan Disease. 2023. PMID: 28613566
- Wolf NI, van der Knaap MS, Engelen M. Treatment of leukodystrophies: Advances and challenges. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2025. PMID: 40279833
- Adam MP, Bick S, Mirzaa GM. Canavan Disease. 1993. PMID: 20301412
- Perlman SJ, Mar S. Leukodystrophies. Advances in experimental medicine and biology. 2012. PMID: 22411242
- Hol EM, Dykstra W, Chevalier J. Neuroglia in leukodystrophies. Handbook of clinical neurology. 2025. PMID: 40148043
- Hartog L, Dekeyzer S, Bossche SV. Alexander Disease. Journal of the Belgian Society of Radiology. 2021. PMID: 34723085